RxDoctor Payments Data

Bruce Kirschner, MD

Ophthalmology · Burlingame, CANPI 1972699015

Payments from drug & device makers

$350,576in general payments, 2019–2025

Across 35 payments — averaging $10,016 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Spinal Surgical Strategies, Inc.$350K
  • AbbVie$304
  • Amgen$120
  • Biotissue Holdings Inc.$67
  • Tarsus Pharmaceuticals, Inc.$24
  • Sun Pharmaceutical Industries Inc.$22
  • plus $39 from 2 others

What the payments were for

  • Food & beverage$55697%
  • Gifts$193%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$350,576 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$132,151
Medicare patients
584
Services billed
1,212

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost53$31,830
RestasisCyclosporine18$21,519
Latanoprost366$7,101
Timolol Maleate125$4,801
XalatanLatanoprost12$3,017
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol21$2,706
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat83$2,362
Travoprost13$1,617
Brimonidine Tartrate42$853
Dorzolamide Hcl18$552
Prednisolone Acetate14$437
ErythromycinErythromycin Base17$159

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis$304$53,34971 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Burlingame

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →